Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study

被引：2

作者：

Autore, Francesco ^{[1
]}

Visentin, Andrea ^{[2
]}

Deodato, Marina ^{[3
]}

Vitale, Candida ^{[4
,5
]}

Galli, Eugenio ^{[1
]}

Fresa, Alberto ^{[1
]}

Fazzi, Rita ^{[6
]}

Sanna, Alessandro ^{[7
]}

Olivieri, Jacopo ^{[8
]}

Scortechini, Ilaria ^{[9
]}

Del Principe, Maria Ilaria ^{[10
]}

Sportoletti, Paolo ^{[11
]}

Schiattone, Luana ^{[12
]}

Maschio, Nilla ^{[13
]}

Facchinelli, Davide ^{[14
]}

Marchesi, Francesco ^{[15
]}

Coscia, Marta ^{[4
,5
]}

Tedeschi, Alessandra ^{[3
]}

Trentin, Livio ^{[2
]}

Innocenti, Idanna ^{[1
]}

Candoni, Anna ^{[8
,16
]}

Busca, Alessandro ^{[4
,5
]}

Pagano, Livio ^{[1
]}

Laurenti, Luca ^{[1
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Largo Agostino Gemelli 8, I-00168 Rome, Italy

[2] Univ Padua, Padua, Italy

[3] ASST Grande Osped Metropolitano Niguarda, Milan, Italy

[4] Univ Torino, AOU Citta Salute & Sci Torino, Turin, Italy

[5] Univ Torino, Dipartimento Biotecnol Mol & Sci Salute, Turin, Italy

[6] Azienda Osped Univ Pisana, Pisa, Italy

[7] Azienda Osped Univ Careggi, Florence, Italy

[8] Clin Ematol Udine, Udine, Italy

[9] Azienda Osped Univ Marche, Ancona, Italy

[10] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenz, Rome, Italy

[11] AO Santa Maria Misericordia Perugia, Perugia, Italy

[12] Presidio Osped S Spirito Pescara, Pescara, Italy

[13] Oncoematol Ist Oncol Veneto IOV IRCCS, Padua, Italy

[14] Osped San Bortolo, Vicenza, Italy

[15] IRCCS Regina Elena Natl Canc Inst, Rome, Italy

[16] Univ Modena & Reggio Emilia, Modena, Italy

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 05期

关键词：

RITUXIMAB;

D O I：

10.1002/ajh.27247

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：982 / 984

页数：3

共 50 条

[41] Disease activity and pretreatment, but not hypogammaglobulinemia, are risk factors for infectious complications in patients with chronic lymphocytic leukemia.
Hensel, M
Yammeni, S
Kornacker, M
Ho, AD
BLOOD, 2002, 100 (11) : 353B - 353B
[42] Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients
Mato, Anthony R.
Tam, Constantine S.
Allan, John N.
Brander, Danielle M.
Pagel, John M.
Ujjani, Chaitra S.
Hill, Brian T.
Lamanna, Nicole
Lansigan, Frederick
Jacobs, Ryan
Shadman, Mazyar
Skarbnik, Alan P.
Pu, Jeffrey J.
Barr, Paul M.
Sehgal, Alison R.
Cheson, Bruce D.
Zent, Clive S.
Tuncer, Hande H.
Schuster, Stephen J.
Pickens, Peter V.
Shah, Nirav N.
Winter, Allison M.
Kennard, Kaitlin
Isaac, Krista
Dorsey, Colleen
Vandegrift, Alexandra Marie
Singavi, Arun K.
Williams, Annalynn
Howlett, Christina
Weissbrot, Hanna
Ali, Naveed
Khajavian, Sirin
Sitlinger, Andrea
Tranchito, Eve
Rhodes, Joanna
Bhavsar, Erica Bharat
Bailey, Neil
Patel, Bhavisha
Burns, Timothy F.
Yacur, Melissa
Malhotra, Mansi
Handunnetti, Sasanka
Svoboda, Jakub
Furman, Richard R.
Nabhan, Chadi
BLOOD, 2017, 130
[43] Impact of COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study
Autore, Francesco
Visentin, Andrea
Deodato, Marina
Vitale, Candida
Galli, Eugenio
Fresa, Alberto
Fazzi, Rita
Sanna, Alessandro
Olivieri, Jacopo
Scortechini, Ilaria
del Principe, Maria Ilaria
Sportoletti, Paolo
Schiattone, Luana
Maschio, Nilla
Facchinelli, Davide
Coscia, Marta
Tedeschi, Alessandra
Trentin, Livio
Innocenti, Idanna
Candoni, Anna
Busca, Alessandro
Pagano, Livio
Laurenti, Luca
LEUKEMIA & LYMPHOMA, 2023, 64 : S27 - S28
[44] Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes
Montalban-Bravo, Guillermo
Short, Nicholas J.
Chien, Kelly S.
Valero, Yesid Alvarado
Daver, Naval
Borthakur, Gautam
Swaminathan, Mahesh
Maiti, Abhishek
Hammond, Danielle E.
Nogueras-Gonzalez, Graciela
Huang, Xuelin
Schneider, Heather
Shelly, Kristen
Kadia, Tapan M.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2023, 142
[45] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 19 - 20
[46] ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia
Davids, Matthew S.
Fischer, Kirsten
Robrecht, Sandra
Zhang, Can
Ahn, Inhye E.
Lura, Michele Porro
Sinai, Wendy
Chyla, Brenda
Sail, Kavita
Pesko, John
Pai, Madhavi
Komlosi, Viktor
Hallek, Michael
Brown, Jennifer R.
Al-Sawaf, Othman
BLOOD, 2021, 138
[47] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Barr, Paul M.
Hill, Brian T.
Ma, Shuo
Baran, Andrea M.
Bui, Andrew
Meacham, Philip J.
Morrison, Ashley
Liesveld, Jane L.
Mulford, Deborah A.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Friedberg, Jonathan W.
Zent, Clive S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 9 - 10
[48] Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience
Autore, Francesco
Innocenti, Idanna
Morelli, Francesca
Sora, Federica
Corbingi, Andrea
Fianchi, Luana
Criscuolo, Marianna
Pagano, Livio
Sica, Simona
Laurenti, Luca
HEMATOLOGICAL ONCOLOGY, 2019, 37 (04) : 496 - 497
[49] Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience
Autore, Francesco
Innocenti, Idanna
Morelli, Francesca
Sora, Federica
Corbingi, Andrea
Soldati, Denise
Fianchi, Luana
Criscuolo, Marianna
Pagano, Livio
Bacigalupo, Andrea
Sica, Simona
Laurenti, Luca
BLOOD, 2018, 132
[50] Chronic Lymphocytic Leukemia (CLL) Advances in the Treatment of High-risk Patients
Schmale, Ine
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (12) : 842 - 842

← 1 2 3 4 5 →